

All MCOs: COVID-19 Vaccine Administration Procedure Codes 0003A and 0013A Are Now Benefits

Background:

On August 12, 2021, the Food and Drug Administration (FDA) issued an amended Emergency Use Authorization for the use of an additional dose of the Pfizer-BioNTech and Moderna COVID-19 vaccines in certain immunocompromised individuals. On August 13, 2021, the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices recommended an additional dose of the COVID-19 vaccine for individuals who are moderately to severely immunocompromised at least 28 days after the second dose of Pfizer-BioNTech or Moderna COVID-19 vaccine.

Key Details:

Effective for dates of service on or after August 12, 2021, COVID-19 vaccine administration codes 0003A (Pfizer-BioNTech) and 0013A (Moderna) are now benefits for Texas Medicaid. Providers may receive reimbursement for the additional dose of COVID-19 vaccine administered to individuals who are moderately to severely immunocompromised at least 28 days after the second dose of Pfizer-BioNTech or Moderna COVID-19 vaccine.

Procedure code 0003A is a benefit for individuals who are 12 years of age and older, and procedure code 0013A is a benefit for individuals who are 18 years of age and older.

Providers may bill retroactively for COVID-19 vaccine administration provided on or after August 12, 2021. Affected claims submitted with these procedure codes for dates of service on or after the effective date must be reprocessed. Providers are not required to appeal the claims unless they are denied for additional reasons after the claims reprocessing is complete.

Providers interested in enrolling as a COVID-19 vaccinator should visit www.dshs.texas.gov/coronavirus/immunize/provider-information.aspx for more information.

Resources:

<https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised>